Key Developments: Pfizer Inc (PFE)

PFE on New York Consolidated

31.25USD
30 Jan 2015
Change (% chg)

$-0.58 (-1.82%)
Prev Close
$31.83
Open
$31.67
Day's High
$31.80
Day's Low
$31.20
Volume
43,070,750
Avg. Vol
25,212,400
52-wk High
$33.50
52-wk Low
$27.51

Search Stocks

Latest Key Developments (Source: Significant Developments)

OPKO Health Inc and Pfizer Inc receives regulatory clearance for global agreement
Thursday, 29 Jan 2015 08:15am EST 

OPKO Health Inc and Pfizer Inc:Says the closing of their worldwide agreement for the development and commercialization of hGH-CTP, a long-acting human growth hormone.The closing follows termination of the waiting period under the Hart-Scott Rodino Act.  Full Article

Pfizer Inc to pay $400 million to avert investor class action trial - Reuters
Tuesday, 27 Jan 2015 02:54pm EST 

Pfizer Inc:Says it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing - Reuters.The accord, which must be approved by a federal judge in Manhattan, came days ahead of a jury trial set for Feb. 10.Filed in 2010, the lawsuit accused Pfizer and various executives of making false statements to shareholders about its off-label marketing of products, including Bextra and other drugs.The lawsuit also contended Pfizer made misleading statements about various government investigations of those practices that led to a $2.3 billion settlement with the U.S. Justice Department in 2009.U.S. District Judge Alvin Hellerstein had named pension fund Stichting Philips Pensioenfonds the lead plaintiff and certified a class of investors who bought Pfizer stock from Jan. 19, 2006 to Jan. 23, 2009.Ahead of trial, Pfizer had sought to block jurors from hearing from the plaintiffs' damages expert, who said the company's stock had been artificially inflated $1.26 a share over the three-year period due to misstatements or omissions.  Full Article

Pfizer Inc gives FY 2015 outlook, revenue below analysts' estimates
Tuesday, 27 Jan 2015 07:00am EST 

Pfizer Inc:Expects FY 2015 reported revenues of $44.5 to $46.5 billion.FY 2015 reported diluted EPS $1.37 to $1.52.FY 2015 adjusted diluted EPS $2.00 to $2.10.FY 2015 revenue of $47.6 billion and EPS of $2.00 - Thomson Reuters I/B/E/S.  Full Article

Pfizer Inc acquires Redvax GmbH
Monday, 5 Jan 2015 07:30am EST 

Pfizer Inc:Says it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren.  Full Article

Pfizer Inc initiates phase 2 study of PF-06252616 in Duchenne Muscular Dystrophy
Wednesday, 17 Dec 2014 08:00am EST 

Pfizer Inc:Announced enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.Says the phase 2 clinical trial will evaluate the safety, tolerability and efficacy of PF-06252616 in boys aged 6 to <10 years old diagnosed with DMD regardless of genotype.  Full Article

Pfizer declares first-quarter 2015 dividend
Monday, 15 Dec 2014 12:06pm EST 

Pfizer Inc:Declares 28-cent first-quarter 2015 dividend on the company's common stock, payable Mar. 3, 2015, to shareholders of record at the close of business on Feb. 6, 2015.Increases the dividend by about 8 percent, to 28 cents from 26 cents per share.  Full Article

OPKO Health and Pfizer enters into global agreement for OPKO's Long-Acting Human Growth Hormone (hGH-CTP)
Monday, 15 Dec 2014 08:00am EST 

OPKO Health Inc and Pfizer Inc:Enters into worldwide agreement for development and commercialization of OPKO's long-acting hGH-CTP for treatment of growth hormone deficiency (GHD) in adults and children.Says as well as for treatment of growth failure in children born small for gestational age (SGA) who fail to show catch-up growth by 2 years of age.hGH-CTP has potential to reduce required dosing frequency of human growth hormone to single weekly injection from current standard of one injection per day.Says hGH-CTP is currently in global phase 3 trial in adults and global phase 2 trial in children and has orphan drug designation in the U.S. and Europe for both adults and children with GHD.Under terms of agreement, OPKO will receive an upfront payment of $295 mln and is eligible to receive up to an additional $275 mln upon achievement of certain regulatory milestones.Pfizer will receive exclusive license to commercialize hGH-CTP worldwide.  Full Article

Diplomat Pharmacy Inc selected as limited-distribution pharmacy partner by Pfizer; Diplomat to dispense Xalkori, Bosulif, Sutent and Inlyta
Wednesday, 3 Dec 2014 04:37pm EST 

Diplomat Pharmacy Inc:Has been selected to Pfizer Inc.'s limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.Says four limited-distribution therapies have each received approval from U.S. Food and Drug Administration for the treatment of specific cancers.  Full Article

Pfizer Inc completes acquisition of Baxter's Marketed Vaccines
Monday, 1 Dec 2014 07:30am EST 

Pfizer Inc:Completes acquisition of Baxter International Inc.'s portfolio of marketed vaccines.Portfolio that was acquired consists of NeisVac-C and FSME-IMMUN/TicoVac.As previously announced, Pfizer also acquired a portion of Baxter's facility in Orth, Austria, where these vaccines are manufactured.  Full Article

Pfizer Inc Forms Global Strategic Alliance with Merck KGaA
Monday, 17 Nov 2014 02:59am EST 

Pfizer Inc:Entered into an agreement with Merck KGaA, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody in development by Merck KGaA as a potential treatment for multiple types of cancer.Pfizer and Merck KGaA will explore the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with Pfizer's and Merck KGaA's broad portfolio of approved and investigational oncology therapies.  Full Article

Pfizer to pay $400 million to avert investor class action trial

NEW YORK - Pfizer Inc said on Tuesday it agreed to pay $400 million to avert a trial in a class action lawsuit accusing the pharmaceutical giant of misleading investors in connection with off-label marketing.

Search Stocks